PURPOSE To compare the accuracy of axial length vergence formulas versus refractive vergence formulas for secondary intraocular lens (IOL) implantation in pediatric aphakia. METHODS This retrospective comparative study, evaluated 31 eyes of 31 patients aged ≤3.5 years, who had undergone secondary IOL implantation. The median absolute error (MedAE) was compared between axial length vergence fo...

Posterior capsulorhexis with optic capture was originally described by Gimbel and DeBroff [4] to maintain a clear visual axis after pediatric cataract surgery. This technique involves capturing the IOL optic through a primary posterior continuous curvilinear capsulorhexis (PCCC), while the haptics remain within the capsular bag (Figure 1). Studies have demonstrated this to be a valuable techniq...

AIM To determine the amount of myopic shift in children after cataract surgery with intraocular lens (IOL) implantation and to evaluate success in achieving the target refraction. METHODS The children were assigned into three groups depending on age at time of surgery: Group A, 0-1 years old; Group B, 1-7 years old; Group C, 7-18 years old. Multiple regression analysis was used to create a fo...

92 CATARACT & REFRACTIVE SURGERY TODAY EUROPE SEPTEMBER 2011 A lthouth vitreoretinal lymphoma, retinal astrocytoma, and choroidal osteoma are rare diseases, they do occur. Therefore, it is important to have clinical suspicion of these entities because proper diagnosis may have important systemic and ocular implications. The general ophthalmologist must stay forever vigilant for causes of visual...

PURPOSE Natural killer (NK) cell neoplasm is a rare disease that follows an acute course and has a poor prognosis. It usually emerges from the nose and appears in the ocular tissue as a metastasis. Herein, we describe a case of NK-cell neoplasm in which the eye was considered to be the primary organ. CASE A 50-year-old female displayed bilateral anterior chamber cells, vitreous opacity, bullo...

CLINICAL CASE A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were  administered. 12 months after the last intravitreal rituximab dose, signs and  symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab  administration were not observed. DISCUSSION Intravitreal rituximab is an ef...